In this situation, tumor PD-L1 expression is not enough to predict the activity of nivolumab on the contrary in TILs rich in T cells CD8+ even with PD-L1 low expression the immune checkpoint inhibitor could stimulate the awakening of competent immune system. The gene discussed is CD274; the disease is neoplasm.